Ceapro Inc. (CZO:TSX.V)has ranked 13th on Alberta Venture`s 2005 list of 25 fastest growing companies, with annual revenues under $20 million.
``We are pleased to move up to the number 13 position from 21st place last year,`` said Dr. Mark Redmond, Ceapro`s President and Chief Executive Officer. ``With the commercialization of our AccuScreen(TM) diabetes test meal and new products in the areas of active ingredients and veterinary therapeutics scheduled for launch during 2005, we are confident in the continued growth of Ceapro as a leader in our field of biotechnology.``
Alberta`s Fastest Growing Companies is presented by Alberta Venture magazine and its founding partner, Grant Thornton Chartered Accountants and Management Consultants. Sponsors include ATB Financial, DeVry Institute of Technology and Miller Thompson LLP. For 2005, Alberta Venture expanded its list from 30 to 50 companies. Half of companies on the list have annual revenues under $20 million and the other half are companies with annual revenues of over $20 million. The full listing of the Fast 50 companies appears in the January/February issue of Alberta Venture.
About Ceapro Inc.
Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro`s shares trade on the TSX Venture Exchange under the symbol CZO. Shares Issued: 34,784,213, recent close: $0.45 (January 4, 2005). To learn more about Ceapro, log on to our new website at www.ceapro.com.
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Capitalization Report for Ceapro Inc
Shares Issued: 34784213
Shares Escrow: 0
TSX Venture closing price for Ceapro Inc Date: 2005/01/04
Closing Price: 0.450
CONTACT: TEL: (780) 421-4555 Dr. Mark Redmond, President and CEO, Ceapro Inc.
